Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Schizophrenia
Interventions
DRUG

Seroquel XR- quetiapine fumarate extended release

Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.

DRUG

Seroquel IR - quetiapine fumarate

Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.

DRUG

Placebo matching Seroquel XR

Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.

DRUG

Placebo matching Seroquel IR

Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.

Trial Locations (20)

Unknown

Research Site, Vienna

Research Site, Middelfart

Research Site, Berlin

Research Site, Bochum

Research Site, Hamburg

Research Site, München

Research Site, Rottweil

Research Site, Giarre

Research Site, Genova

Research Site, Lido di Camaiore

Research Site, Barakaldo (vizcaya)

Research Site, Tivoli

Research Site, Sant'Arsenio

Research Site, Sassari

Research Site, Borgomanero

Research Site, Catania

Research Site, Roma

Research Site, Torre Annunziata

Research Site, Salamanca

Research Site, Zamora

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01213836 - Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia | Biotech Hunter | Biotech Hunter